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A B S T R A C T
Background: Isoniazid Preventive Therapy (IPT) is a proven public health tool to reduce Tuberculosis (TB)
among people living with HIV. However, its implementation in most countries is suboptimal. This
retrospective study was conducted to determine the coverage and factors associated with IPT initiation to
inform program scale up and improve quality of service in Tanzania and elsewhere.
Methods: Retrospective cohort study design involving HIV clinics in Dar es Salaam, Iringa and Njombe
regions from January 2012 to December 2016.
Results: A total of 171,743 PLHIV were in the cohort from 2012 to 2016. Of these, 166,709 were involved in
the analysis. Of those analyzed, 23,970 (14.38%) were ever initiated on IPT. Female sex (aOR = 1.72, 95% CI:
1.13, P < 0.001), obesity (aOR = 1.29, 95% CI:1.201.39, P < 0.001), WHO clinical stage II (aOR = 1.48, 95% CI:
1.421.55, P < 0.001), enrolment in hospitals (aOR = 1.98, 95% CI: 1.892.06, P < 0.001), enrolment in
Njombe region (aOR = 1.25: 95% CI: 1.181.33, P < 0.001) and enrolment in public health facilities (aOR =
1.93: 95% CI: 1.822.04, P < 0.001) were associated with increased IPT uptake. Being on ART (aOR = 0.67,
95% CI: 0.650.70, P < 0.001) and severe nutritional status (aOR = 0.72, 95% CI: 0.600.88, P < 0.001) were
associated with decreased IPT initiation.
Conclusions: Our study documented low IPT initiation in the study area as well as documented factors
which enable IPT initiation and those which impair IPT initiation. Strategies are needed to work on
barriers and sustain enabling factors to improve IPT coverage.
© 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Background
Tuberculosis (TB) among people living with HIV (PLHIV) is still a
public health concern (WHO, 2018) causing increased morbidity
and mortality (Dravid et al., 2019). TB disease among PLHIV
threatens the benefits gained through other interventions such as
antiretroviral Therapy (ART) (Diwakar et al., 2020) and such
interferences may affect achieving Sustainable Development Goals
and Joint United Nations Programme on HIV/AIDS goals of ending
AIDS epidemics by 2030 (UNAIDS, 2014). Worldwide, in 2018, 9% of
individuals diagnosed with TB disease were HIV positive. Fifty-one
percent, of those with HIV had TB disease with 84% of these being
on ART. There were 1.3 million, among people diagnosed with TB
and 300,000 (23%) were HIV positive (WHO, 2018). Tanzania was
ranked among 30 countries in the World with high TB burden in
2018. TBHIV co-infection among confirmed TB patients was 28%,
and TBHIV mortality rate due to TBHIV co-infection was 29 per
100,000 population which accounted for up to 73% of all deaths
among TB patients (UNAIDS, 2019; Mollel et al., 2019).
Isoniazid Preventive Therapy (IPT) which entails use of an anti-
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LHIV in real world settings. The effect is even more when IPT is
sed in combination with ART (Yirdaw et al., 2019; Golub et al.,
011; Shayo et al., 2017). Following this, the World Health
rganization (WHO) recommends that IPT is part of comprehen-
ive HIV care and treatment package (WHO, 1998).
Despite available evidence on the benefits of IPT on PLHIV, use
f this effective preventive tool is suboptimal (Lester et al., 2010;
rant et al., 2005; Ayele et al., 2015; Makoni et al., 2015).
uboptimal implementation of IPT is equally present even in parts
f the world hard-hit by both HIV and TB such as Sub-Saharan
frica (Wilkinson and Davies, 1997) where service is needed most.
n 2017, IPT among PLHIV Worldwide ranged from 1% in Eswatini to
3% in South Africa (WHO, 2018). Reasons for low IPT coverage
ange from health provider factors, to client factors, to general
ealth system factors (Lester et al., 2010; Mindachew et al., 2014).
Tanzania has been implementing the use of IPT among PLHIV in
IV care and treatment clinics to prevent development of TB
iseases since 2011 (Sabasaba et al., 2019). Here we describe
haracteristics of PLHIV who were screened TB negative (prereq-
isite for IPT initiation), determine characteristics of PLHIV who
nitiated IPT as well as determine factors associated with IPT
nitiation as IPT has been recently integrated in HIV care and
reatment clinics in Tanzania. The findings from this study will
nform IPT program scale up in Tanzania and elsewhere.
ethods
tudy design and setting
We described a secondary data analysis of a retrospective
ohort study using the STROBE checklist (Cuschieri, 2019).
nonymized data from all PLHIV enrolled in 315 HIV care and
reatment clinics (CTCs) in Dar es Salaam, Iringa and Njombe
egions over the period from January 2012 to December 2016.
ringa and Njombe regions have higher HIV prevalence, above the
ational average (URT, 2018) and Dar es Salaam to has the highest
B case notifications in the country (Said et al., 2017).
tudy population
This study used retrospective data collected from PLHIV
nrolled in HIV care and treatment clinics in the three regions
nrolled in the specified study period. PLHIV who had TB disease
iagnosis before CTC enrolment and those who attended clinics in
ealth facilities which never implemented IPT throughout the
tudy period were excluded from the analysis.
ata collection
In Tanzania TB management is integrated in HIV care and
reatment services to reduce TB among PLHIV. Information
egarding the cohort is detailed elsewhere (Maokola et al.,
020). In summary, three interventions to reduce TB are
mplemented in HIV care and treatment clinics; these are
ntensified TB case finding (ICF), IPT and TB infection prevention
nd control. During every clinic visit PLHIV are screened for active
B using symptoms/signs as part of ICF. Those who are found with
t least one symptom or sign of TB undergo further laboratory and
adiological investigations to diagnose TB disease. Those who are
related to TB are electronically captured at health facility level into
an electronic database called the CTC2 database. Data from the
CTC2 database is transferred to the national level database (CTC3)
in real time, where demographic and clinical information of each
PLHIV identified only by their unique identification CTC number is
available for analysis.
Information for PLHIV enrolled in the three study regions were
extracted from the CTC3 database. The extracted database had the
following variables: The extracted database contained study
participant unique identification, information regarding demo-
graphic data of the study participants, characteristics of the health
facilities, clinical information of the study participants including
ART information and TB management. The data were cleaned by
checking missing values and abnormal entries. STATA version 14
was used for data analysis. Demographic and clinical variables
were used as independent variables and IPT status (received/not
received) was the dependent variable. PLHIV with missing data for
covariates were excluded from the analyses on a case by case basis,
giving a complete case analysis. Missing data were most frequent
for clinical characteristics which are not routinely measured in
CTC, although these are available at baseline (enrolment into the
clinic). As less than 1% of PLHIV were missing these clinical
characteristics, the analysis was conducted based on complete case
analysis.
Descriptive analysis was used to describe baseline character-
istics of study participants and uptake of IPT. Multivariate logistic
regression was used to determine factors associated with IPT
initiation status involving only exposure variables which were
statistically significant during univariate analysis. Multilevel
analysis was done to account for cluster effects at the health
facility. A statistical significance level of 5% was used.
Results
Baseline characteristics of study participants
A total 171,743 PLHIV were enrolled in CTCs in the 3 regions
during the study period from 2012 to 2016. Four (UNAIDS, 2014)
percent of study participants were excluded from the analysis as
they either had TB before CTC enrolment or they were in clinics
which never implemented IPT throughout the study period. Hence,
166,709 were included in the final analysis; of these 23,970 were
initiated on IPT (Figure 1).Figure 1. IPT initiation cascade among PLHIV attending CTC during the follow up
period.ound to have no symptoms/signs of active TB are offered IPT for at
east 6 months provided other criteria are fulfilled. TB infection and
revention measures are also implemented in all HIV care and
reatment clinics to reduce TB infection transmission.
CTCs have patient-level data collection containing data on every
isit made by PLHIV. For up to 80% of clinics, data including those563
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2549 (71.98%), with walking functional status (95.95%), not on
ART (64.79%), with normal nutritional status (92.01%) and normal
BMI (56.33%). Study participants were also more likely to be WHO
clinical stage I (36.58%), enrolled in 2014 (21.20%), from dispensary
level (37.71%), with good adherence to ARV (98.54%), enrolled in
Dar es Salaam (72.12%) and from public health facilities (72.82%)
(Table 1).
Characteristics of study participants initiated on IPT
Most of those initiated on IPT were females (71.41%), aged
2549 years (77.40%), with walking functional status (97.25%), not
on ART (72.23%), with normal nutritional status (93.31%) and
attended in hospitals (48.86%). Moreover, most of those initiated
Table 1
Baseline characteristics of study participants (N = 166,709).
Characteristics Frequency, n Percentage, %
IPT status
Never on IPT 142,739 85.62%



























Stage I 60,191 36.58%
Stage II 39,252 23.85%
Stage III 52,667 32.00%















Dar es Salaam 120,383 72.12%
Table 2
Characteristics of study participants initiated on Isoniazid Preventive Therapy.
Covariate IPT status Total
IPT-No IPT-Yes
Sex
Male 45,539(31.90%) 6852(28.59%) 52,391
Female 97,200(68.10%) 17,118(71.41%) 114,318
Age (Years):
09 6987(4.90%) 533(2.22%) 7520
1019 6637(4.65%) 705(2.94%) 7342
2024 14,164(9.92% 1720(7.18%) 15,884
2549 101,441(71.07%) 18,552(77.40%) 119,993
+50 13,501(9.46%) 2460(10.26%) 15,961
Functional status
Ambulatory 4844(3.41% 516(2.16%) 5360
Bedridden 1226(0.86%) 140(0.59%) 1366
Walking 136,039(95.73% 23,207(97.25%) 159,246
ART status
ART-No 90,009(63.52%) 17,210(72.23%) 107,219
ART-Yes 51,690(36.48%) 6584(27.67%) 58,274
Nutritional status
Normal 124,761(91.79%) 21,559(93.31%) 146,320
Moderate 9558(7.03%) 1387(6.00%) 10,945
Severe 1596(1.17%) 159(0.69%) 1755
BMI
Underweight 16,376(18.05%) 2630(14,85%) 19,006
Normal 50,879(56.08% 102,020(57.59%) 61,081
Overweight 15,989(17.62%) 3327(18.78%) 19,316
Obesity 7479(8.24%) 1557(8.79%) 9036
WHO clinical stage
Stage I 52,411(37.20%) 7780(32.87%) 60,191
Stage II 32,948(23.39%) 6304(26.63%) 39,252
Stage III 44,526(31.60%) 8141(34.39%) 52,667
Stage IV 11,008(7.81%) 1447(6.11%) 12,455
Enrolment Year
2012 25,781(18.06%) 4315(18.00%) 30,096
2013 28,045(19.65%) 4930(20.57%) 32,975
2014 29,880(20.93%) 5464(22.80%) 35,344
2015 27,297(19.12%) 4.750(19.82%) 32,047
2016 31,736(22.23%) 4511(18.82%) 36,247
Health Facility level
Dispensary 56,931(39.88%) 5934(24.76%) 62,865
Health Center 38,236(26.79%) 6325(26.39%) 44,561
Hospital 47,572(33.33%) 11,711(48.86%) 59,283
ARV adherence
Good 27,611(98.48%) 5590(98.98%) 31,201
Poor 426(1.52%) 37(1.02%) 463
Region





Iringa 17,176(12.03%) 986(4.11%) 18,162
Njombe 23,330(16.34%) 4834(20.17% 28,164
Health Facility ownership
Private 41,559(29.12% 3750(15.64%) 45,309
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34.39%), enrolled in 2014 (22.80%), with good adherence to ARVs
98.98%) and enrolled in public health facilities (84.36) (Table 2).
eterminants of IPT initiation
In multivariate analysis; sex, functional status, ART status,
utritional status, BMI, WHO Clinical stage, health facility type,
dherence to ARVs, region and health facility ownership, had
tatistical significant association with IPT initiation. Female sex
aOR = 1.72, 95% CI: 1.13, P < 0.001), obesity (aOR = 1.29, 95%
I:1.201.39, P < 0.001), WHO clinical stage II (aOR = 1.48, 95% CI:
.421.55, P < 0.001), enrolment in hospitals (aOR = 1.98, 95% CI:
.892.06, P < 0.001), enrolment in Njombe region (aOR = 1.25:
5% CI: 1.181.33, P < 0.001) and enrolment in public health
acilities (aOR = 1.93: 95% CI: 1.822.04, P < 0.001) were associated
ith increased IPT uptake. Being on ART (aOR = 0.67, 95% CI:
.650.70, P < 0.001) and severe nutritional status (aOR = 0.72, 95%
I: 0.600.88, P < 0.001) were associated with decreased IPT
nitiation. (Table 3).
iscussion
The study registered low uptake of IPT among PLHIV. Female
ex, ART, obesity, WHO clinical stage, enrolment in Njombe region,
nd being in public hospitals were the determinants of IPT
nitiation.
Only about 80% of the HIV clinics in the country had an
electronic HIV database and hence were capable of contributing
data to the national database. Health facilities at low levels did not
have electronic databases and were unable to contribute data.
Secondly, the analysis included 3 regions out of 26 regions. These
regions were purposively chosen as they had the highest HIV and
TB prevalence. They may therefore not represent a true picture of
other regions which were not involved in the analysis.
Our study registered lower IPT initiation compared to other
studies which were also conducted in routine settings in
Zimbabwe, Ethiopia and Nepal (Makoni et al., 2015; Nyathi
et al., 2019; Yirdaw et al., 2019; Teklay et al., 2016; Wesen and
Mitike, 2012; Dhungana et al., 2019). These studies documented
IPT initiation ranging from 20% to 54%. The observed low IPT
initiation in the current study needs further research. Neverthe-
less, most of the studies, despite being conducted in routine
settings like our study, involved small numbers of health facilities.
None of the above studies involved more than 20 high level health
facilities. Our study involved a total of 315 in the 3 regions
containing a mix of high and low level health facilities. Shortage of
INH, fear of INH resistance, lack of confidence in ruling out TB
disease, lack of commitment among providers and hesitancy in
accepting IPT among clients were among the barriers for IPT
implementation documented in several other studies (Nyathi et al.,
2019; Teklay et al., 2016; Wesen Denegetu and Lovely Dolamo,
2014). Improvement in recording and reporting in order to identify
PLHIV who are eligible for IPT, health education to curb fear of
able 3
actors associated with IPT initiation (N = 166,709).
Covariate Univariate analysis Multivariate analysis
cOR, 95% CI, P-value aOR, 95% CI, P-value
Sex
Male 1 1
Female 1.20(1.161.23), P < 0.001 1.72(1.131.22), P < 0.001
ARV status
ART-No 1 1









Obesity 1.36(1.271.46), P < 0.001 1.29(1.201.39), P < 0.001
WHO clinical stage
Stage I 1 1
Stage II 1.23(1.181.27) 1.48(1.421.55)
Stage III 1.13(1.101.17) 1.23(1.181.28)
Stage IV 0.79(0.750.84), P < 0.001 0.88(0.810.95), P < 0.001
Health Facility level
Dispensary 1 1
Health Center 1.43(1.381.49) 1.73(1.661.82)
Hospital 2.04(1.972.11), P < 0.001 1.98(1.892.06), P < 0.001
Region
Dar es Salaam 1 1
Iringa 0.32(0.300.35) 0.39(0.350.42)
Njombe 1.17(1.131.21), P < 0.001 1.25(1.181.33), P < 0.001
Health Facility ownership
Private 1 1
Public 2.21(2.132.30), P < 0.001 1.93(1.822.04), P < 0.001
95% Confidence Interval.
565
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staff workload and avoiding INH stockout are the interventions
recommended to improve IPT coverage (Teklay et al., 2016;
Ogunsola et al., 2019; Legese et al., 2020) which could be applied
in our setting as well.
Consistent with our study, other studies also documented a
high IPT initiation among females, ART recipients, PLHIV enrolled
in public hospitals and PLHIV with relatively good health (WHO
clinical stage II) (Nyathi et al., 2019; Trinh et al., 2016; Van
Ginderdeuren et al., 2019; Ayele et al., 2017). High uptake among
females could be due to more health information for women
during medical encounters such as maternal and child health
services (Wesen Denegetu and Lovely Dolamo, 2014). ART
experience and recipients’ good health may increase confidence
for IPT initiation among health care providers.
In our study determinants of IPT initiation were female sex, ART,
obesity and WHO clinical stage II. Other IPT initiation determinants
were enrolment in the Njombe region and in public hospitals. As
stated above, females have a higher threshold embracing health
services due to their health-seeking behavior (Thompson et al.,
2016) as well as their increased opportunity to encounter health
care providers for reproductive health (Wesen Denegetu and
Lovely Dolamo, 2014). Other studies also found an association
between female sex and IPT uptake (Adeniyi et al., 2019). We also
found IPT initiation to be associated with health individuals (WHO
clinical stage II). Our finding is in agreement with what was found
in Kenya (Nyathi et al., 2019). The reason for avoiding IPT in
severely ill PLHIV can be attributed to fear of clinicians due to
difficulty in ruling out TB disease in this population as speculated
in the Kenyan study (Nyathi et al., 2019). High IPT initiation in
hospitals and public health facilities could be explained by the fact
that IPT was rolled out gradually starting with Hospitals. Higher
initiation in public versus in private health facilities could be due to
a slower pace of private health facilities in implementing new
policies in comparison with public owned health facilities
(Buregyeya et al., 2017). Higher IPT initiation in Iringa and Dar
es Salaam in comparison with Njombe explains dynamics in IPT
implementation, which also differs from health facility to health
facility, as reported in another study showing different implemen-
tation levels in different places (Dhungana et al., 2019; Omondi
et al., 2018; Ngugi et al., 2020).
Conclusion
Our study, which used routine HIV data from 315 clinics,
documented low IPT initiation proportion among those who were
enrolled in HIV care and eligible for IPT in Dar es Salaam, Iringa and
Njombe during the study period. Variations in IPT initiation among
regions signal different dynamics affecting IPT uptake in different
regions and hence require customized approaches in quality
improvement. Implementation research is needed to understand
health systems as well as cultural barriers in the uptake of IPT
intervention and design quality improvement initiative accord-
ingly.
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